MDNA - Medicenna names immuno-oncology expert Mann Muhsin as chief medical officer

Medicenna Therapeutics (MDNA) announces the appointment of Mann Muhsin as the company’s chief medical officer.Muhsin has more than 20 years of experience in medical practice and drug development, and has a track record of innovation in oncology and immuno-oncology trial design.Muhsin has designed and executed early and late stage oncology trials for companies such as Oncosec, Halozyme Therapeutics, HUYA Bioscience and most recently at Nektar Therapeutics.

For further details see:

Medicenna names immuno-oncology expert Mann Muhsin as chief medical officer